Abstract
Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Current Aging Science
Title: Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Volume: 3 Issue: 2
Author(s): Sonia C. Correia, Renato X. Santos, Susana Cardoso, Cristina Carvalho, Maria S. Santos, Catarina R. Oliveira and Paula I. Moreira
Affiliation:
Keywords: Alzheimer's disease, estrogen, IGF-1, mitochondria, neuroinflammation, neuroprotection
Abstract: Over the last decades estrogen has been recognized to be involved in normal brain function due to its neurothrophic and neuroprotective effects. Estrogen is intimately associated with neuronal survival, mitochondrial function, neuroinflammation and cognition through genomic as well as non-genomic pathways. It is also known that the neuroprotective actions mediated by estrogens are interlinked with the insulin-like growth factor-1 (IGF-1) signaling pathway. This review is mainly devoted to explore the physiological and pathophysiological effects of estrogen and its signaling pathways in the brain. The molecular mechanisms underlying these effects are also debated. Finally, we discuss the potential neuroprotection afforded by estrogens in Alzheimers disease pathophysiology focusing in the “window of opportunity” for the initiation of estrogen therapy as a critical factor in the fight against neurodegeneration.
Export Options
About this article
Cite this article as:
C. Correia Sonia, X. Santos Renato, Cardoso Susana, Carvalho Cristina, S. Santos Maria, R. Oliveira Catarina and I. Moreira Paula, Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?, Current Aging Science 2010; 3 (2) . https://dx.doi.org/10.2174/1874609811003020113
DOI https://dx.doi.org/10.2174/1874609811003020113 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Amyloidophilic Compounds for Prion Diseases
Infectious Disorders - Drug Targets Recent Developments on Multi-Target-Directed Tacrines for Alzheimer's Disease. I. The Pyranotacrines
Current Topics in Medicinal Chemistry Statin-Like Drugs for the Treatment of Brain Cholesterol Loss in Alzheimers Disease
Current Drug Safety Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA Dynamic Medicinal Chemistry in the Elaboration of Morphine-6- Glucuronide Analogs
Current Topics in Medicinal Chemistry Induction of Cellular Oxidative Stress by the β-amyloid Peptide Involved in Alzheimers disease
Protein & Peptide Letters Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point
Anti-Cancer Agents in Medicinal Chemistry Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Innate and Adaptive Immune Responses in Allergic Contact Dermatitis and Autoimmune Skin Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
Current Drug Research Reviews Alpha-1-Adrenergic Receptor Blockade Modifies Insulin-Regulated Aminopeptidase (IRAP) Activity in Rat Prostate and Modulates Oxytocin Functions
Drug Metabolism Letters Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design